{"id":35990,"date":"2015-05-12T07:29:17","date_gmt":"2015-05-12T11:29:17","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35990"},"modified":"2015-05-12T07:29:17","modified_gmt":"2015-05-12T11:29:17","slug":"actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990","title":{"rendered":"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners&#8217; Eye Drug"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Actavis plc (NYSE:ACT)<\/strong> is on track with maintaining its promise to <strong>Allergan, Inc. (NYSE:AGN)<\/strong> through the upcoming introduction of phase III trials for abicipar. The drug is licensed by Sweden-based Molecular Partners.<\/p>\n<p style=\"text-align: justify;\">The drug is the first of the projects that have a direct influence on the $66 million merger. Ambicipar is a promising drug whose sole purpose is to target age-influenced macular edema. The drug works by restricting VEGF. Allergan licensed the drug from Molecular Partners back in 2011, holding in faith that the company\u2019s technology could revolutionize aspects for future treatments.<\/p>\n<p style=\"text-align: justify;\">Part of the reason Allergan had so much faith in the drug is because it offered effectiveness similar to that of existing antibody therapies. However, the advantage lies in the fact that the drug did not have any toxic risks. It was easier to manufacture, and its production costs were better compared to the others in comparison.<\/p>\n<p style=\"text-align: justify;\">It its long interaction with Allergan, Actavis took an oath to push the Abicipar drug program forward. By the end of the first quarter, the firm revealed its initial earnings on the project. It even went ahead to renew its commitment to the pledge by affirming that it will initiate phase III trials either by the end of the second quarter or by the beginning of the third one.<\/p>\n<p style=\"text-align: justify;\">The drug research institute plans on identifying whether the eye treatment drug can be used to treat wet AMD without the need for any if not all of the many injections required. If the trials are successful, the drug will be preferred over other treatments.<\/p>\n<p style=\"text-align: justify;\">Molecular Partners is has a lot of faith in the technology incorporated in the drug manufacture process as well as the research and development involved by the two collaborating firms. The company&#8217;s COO, Patrick Amstutz announced in a statement that his company is pleased with the commitment levels that Actavis is bringing onto the table. He was also thankful for the Actavis plc (NYSE:ACT) team for prioritizing the development of Abicipar.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Actavis plc (NYSE:ACT) is on track with maintaining its promise to Allergan, Inc. (NYSE:AGN) through the upcoming introduction of phase III trials for abicipar. The [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":15695,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[7224,6035,2048,6036,11468],"stock_ticker":[],"class_list":["post-35990","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-actavis-plc-nyseact","tag-allergan-inc-nyseagn","tag-nyseact","tag-nyseagn","tag-patrick-amstutz","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners&#039; Eye Drug - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners&#039; Eye Drug - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Actavis plc (NYSE:ACT) is on track with maintaining its promise to Allergan, Inc. (NYSE:AGN) through the upcoming introduction of phase III trials for abicipar. The [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-12T11:29:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"586\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners&#8217; Eye Drug\",\"datePublished\":\"2015-05-12T11:29:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990\"},\"wordCount\":351,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg\",\"keywords\":[\"Actavis plc (NYSE:ACT)\",\"Allergan Inc. (NYSE:AGN)\",\"NYSE:ACT\",\"NYSE:AGN\",\"Patrick Amstutz\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990\",\"name\":\"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners' Eye Drug - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg\",\"datePublished\":\"2015-05-12T11:29:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg\",\"width\":1024,\"height\":586},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners&#8217; Eye Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners' Eye Drug - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990","og_locale":"en_US","og_type":"article","og_title":"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners' Eye Drug - Wall Street PR","og_description":"Actavis plc (NYSE:ACT) is on track with maintaining its promise to Allergan, Inc. (NYSE:AGN) through the upcoming introduction of phase III trials for abicipar. The [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-05-12T11:29:17+00:00","og_image":[{"width":1024,"height":586,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners&#8217; Eye Drug","datePublished":"2015-05-12T11:29:17+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990"},"wordCount":351,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg","keywords":["Actavis plc (NYSE:ACT)","Allergan Inc. (NYSE:AGN)","NYSE:ACT","NYSE:AGN","Patrick Amstutz"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990","url":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990","name":"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners' Eye Drug - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg","datePublished":"2015-05-12T11:29:17+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Actavis-plc.jpg","width":1024,"height":586},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/actavis-plc-nyseact-keeps-its-phase-iii-promise-with-molecular-partners-eye-drug-35990#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners&#8217; Eye Drug"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35990"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35990\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/15695"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35990"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}